Detail akcie BIOMED-LUBLIN online

Business Summary: Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, Synthaverse SA revenues increased 7% to PLN38.5M. Net income decreased 76% to PLN890K. Revenues reflect Traditional Segment increase from PLN10.8M to PLN22.9M, BCG Segment increase of 32% to PLN15.5M, Other Countries segment increase of 60% to PLN16.3M, Poland segment increase of less than 1% to PLN17.4M. Net income was offset by BCG Segment income decrease of 38% to PLN2M.